No description available.

No description available.

Age-related macular degeneration (AMD) is the most common cause of vision loss in America for people over the age of 60. Due to damage to the retina, symptoms normally include blurred central vision, difficulty reading, and seeing shadows. While there is no cure for the disease, there are treatments that slow its progression and can restore vision. The treatments explored in this paper are: anti-vascular endothelial growth factor (VEGF) drugs, photodynamic therapy (PDT) and steroids. All three require invasive eye procedures that carry their own risks. The possibility of more effective treatments by combining these therapies is being tested through clinical trials. Studies of combined PDT and anti-VEGF, combined PDT and steroids, and anti-VEGF monotherapy were reviewed, comparing changes in average visual acuity, foveal thickness, and number of injections administered. PDT and anti-VEGF was concluded to be the most efficient of the three, requiring fewer injections while showing an increase in visual acuity similar to anti-VEGF monotherapy.

No description available.

No description available.

Thesis (Ed.D.)--Boston University / PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you. / 2031-01-01

Age-related Macular Degeneration (AMD) is the leading cause of irreversible vision loss among elderly people in developed countries. The non-neovascular or “dry” form of AMD accounts for 85%, whereas the neovascular or “wet” accounts for 15%, of all cases. There are no effective treatments for dry AMD mainly because the molecular mechanisms that lead to the development and progression of AMD are not fully understood. Similarly, while wet AMD is being treated with antibodies against vascular endothelial growth factor (VEGF), the underlying cause that results in the development of wet AMD remains elusive. Cytosolic accumulation of nuclear-DNA (nDNA) fragments has been found to trigger inflammation and mediate the development of multiple diseases. Because inflammation plays a pivotal role in AMD pathogenesis, we thus investigated if accumulation of cytosolic nDNA also contributes to AMD. Our data show that cytosolic nDNA is enriched in macular retinal pigment epithelium (RPE) cells of AMD patients. To study the effect of cytosolic nDNA on RPE cells, we mimicked this pathology by deleting the lysosomal endonuclease Dnase2a, which is responsible for degrading DNA fragments, using CRISPR/Cas9. This resulted in cytosolic accumulation of nDNA in cultured primary human RPE cells as well as in the RPE cell line ARPE-19. Importantly, both RPE cell types with Dnase2a loss became senescent and secreted higher levels of VGEF and pro-inflammatory cytokines compared to control. These effects were mediated by the DNA sensor STING and mTOR pathway. Additionally, similar to other senescent cells, these senescent RPE cells secreted factors that acted in a paracrine manner turning otherwise healthy RPE cells into senescent cells that start secreting VEGF as well as pro-inflammatory cytokines. Finally, we found that mice with Dnase2a deletion develop features of AMD-like retinopathy, including drusen- like deposits, thickened Bruch’s membrane, RPE damage, photoreceptor atrophy, and reduced electroretinogram. The pleiotropic downstream effects of cytosolic accumulation of nDNA in RPE cells, which are consistent with the complex AMD pathology, suggest that this phenomenon contributes to the pathogenesis of AMD and thereby opens new opportunities for therapeutic interventions. / 2020-10-24T00:00:00Z

No description available.

No description available.

The purpose of this study is to examine the association between serum bilirubin and the development of age-related macular degeneration (AMD). The study design includes the utilization of a USA-nationally representative population based cross-sectional study in the National Health and Nutrition Examination Survey: specifically, the NHANES III and continuous NHANES from years 2005-2008. 15,501 survey participants from the NHANES studies chosen for this analysis were interviewed for demographic, behavioral, and medical information, put through a comprehensive medical examination segment, and a laboratory analysis portion. The 15,501 participants were chosen based on their age (40 and above) and the presence of fundus photographs. Fundus photographs were graded using standardized protocol to diagnose early and later AMD, which were combined to form the outcome "AMD" in a binary variable. Serum bilirubin levels were measured using spectrophotometry. Of the 15,501 participants in the study, 1305 (8.9%) were diagnosed with AMD. In a multivariate logistic regression adjusted for age, sex, smoking status, race, and serum C-reactive protein (CRP) levels, bilirubin was significantly associated with AMD (odds ratio, 0.728; confidence interval, 0.547-0.969; P value, 0.0296). The findings of this study indicate that the antioxidative effects of bilirubin may play protective role in the pathology of AMD.